(NASDAQ: CASI) Casi Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.
Casi Pharmaceuticals's earnings in 2025 is -$39,258,000.On average, 1 Wall Street analyst forecast CASI's earnings for 2025 to be -$32,069,643, with the lowest CASI earnings forecast at -$32,069,643, and the highest CASI earnings forecast at -$32,069,643. On average, 1 Wall Street analyst forecast CASI's earnings for 2026 to be -$16,886,913, with the lowest CASI earnings forecast at -$16,886,913, and the highest CASI earnings forecast at -$16,886,913.
In 2027, CASI is forecast to generate -$16,731,987 in earnings, with the lowest earnings forecast at -$16,731,987 and the highest earnings forecast at -$16,731,987.